Results of decitabine (5-aza-2′deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia

Cancer

Volumn 98, Issue 3, 2003, Pages 522-528

  Kantarjian, Hagop M ^a   O'Brien, Susan ^a   Cortes, Jorge ^a   Giles, Francis J ^a   Faderl, Stefan ^a   Issa, Jean Pierre ^a   Garcia Manero, Guillermo ^a   Rios, Mary Beth ^a   Shan, Jianqin ^a   Andreeff, Michael ^a   Keating, Michael ^a   Talpaz, Moshe ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chronic myelogenous leukemia; Decitabine; Myelosuppressive complications; Response

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; IMATINIB;

ADOLESCENT; ADULT; AGED; ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER GROWTH; CARDIOTOXICITY; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DIARRHEA; DNA METHYLATION; DOSE RESPONSE; DRUG FEVER; FATIGUE; HUMAN; MAJOR CLINICAL STUDY; MIXED INFECTION; MYCOSIS; NAUSEA; PHILADELPHIA 1 CHROMOSOME; PNEUMONIA; PRIORITY JOURNAL; TUMOR GROWTH; VOMITING;

ADOLESCENT; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; BLAST CRISIS; DNA MODIFICATION METHYLASES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LEUKEMIA, MYELOID, CHRONIC; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MALE; MIDDLE AGED;

EID: 0037962005     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11543     Document Type: Article

References (24)

1. Jones PA. DNA methylation errors and cancer. Cancer Res. 1996;56:2463-2467.
2. Issa JP, Baylin SB, Herman JG. DNA methylation changes in hematologic malignancies: biologic and clinical implications. Leukemia. 1997;11 (Suppl 1):S7-11.
3. Ben Yehuda D, Krichevsky S, Rachmilewitz EA, et al. Molecular follow-up of disease progression and interferon therapy in chronic myelocytic leukemia. Blood. 1997;90:4918-4923.
4. Issa JP, Kantarjian H, Mohan A, et al. Methylation of the ABL1 promoter in chronic myelogenous leukemia: lack of prognostic significance. Blood. 1999;93:2075-2080.
5. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20:2429-2440.
6. Lubbert M. DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action. Curr Top Microbiol Immunol. 2000;249:135-164.
7. Willemze R, Archimbaud E, Muus P. Preliminary results with 5-aza-2′-deoxycytidine (DAC)-containing chemotherapy in patients with relapsed or refractory acute leukemia. The EORTC Leukemia Cooperative Group. Leukemia. 1993;7 (Suppl 1):49-50.
8. Willemze R, Suciu S, Archimbaud E, et al. A randomized phase II study on the effects of 5-aza-2′-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893). Leukemia. 1997;11(Suppl 1):S24-S27.
9. Pinto A, Zagonel V, Attadia V, et al. 5-Aza-2′-deoxycytidine as a differentiation inducer in acute myeloid leukaemias and myelodysplastic syndromes of the elderly. Bone Marrow Transplant. 1989;4(Suppl 3):28-32.
10. Petti MC, Mandelli F, Zagonel V, et al. Pilot study of 5-aza-2′-deoxycytidine (decitabine) in the treatment of poor prognosis acute myelogenous leukemia patients: preliminary results. Leukemia. 1993;7(Suppl 1):36-41.
11. Richel DJ, Colly LP, Kluin-Nelemans JC, Willemze R. The antileukaemic activity of 5-aza-2 deoxycytidine (Aza-dC) in patients with relapsed and resistant leukaemia. Br J Cancer. 1991;64:144-148.
12. Zagonel V, Lo RG, Marotta G, et al. 5-Aza-2′-deoxycytidine (decitabine) induces trilineage response in unfavourable myelodysplastic syndromes. Leukemia. 1993;7(Suppl 1):30-35.
13. Momparler RL, Rivard GE, Gyger M. Clinical trial on 5-aza-2′-deoxycytidine in patients with acute leukemia. Pharmacol Ther. 1985;30:277-286.
14. Kantarjian HM, O'Brien SM, Keating M, et al. Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia. Leukemia. 1997;11:1617-1620.
15. Kantarjian HM, Dixon D, Keating MJ, et al. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer. 1988;61:1441-1446.
16. Kantarjian HM, Keating MJ, Talpaz M, et al. Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients. Am J Med. 1987;83:445-454.
17. Kantarjian HM, Cortes J, O'Brien S, et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood. 2002;99:3547-3553.
18. Kantarjian HM, Smith TL, O'Brien S, Beran M, Pierce S, Talpaz M. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service. Ann Intern Med. 1995;122:254-261.
19. Wijermans P, Lubbert M, Verhoef G, et al. Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. Clin Oncol. 2000;18:956-962.
20. Wijermans PW, Luebbert M, Verhoef G. Low dose decitabine for elderly high risk MDS patients: who will respond [abstract]? Blood. 2002;100:96a.
21. Issa J-P, Garcia-Manero G, Mannari R, et al. Minimal effective dose of the hypomethylating agent decitabine in hematopoietic malignancies [abstract]. Blood. 2001;98:594a.
22. Sacchi S, Kantarjian H, O'Brien S, et al. Chronic myelogenous leukemia in nonlymphoid blastic phase. Analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer. 1999;86:2632-2641.
23. Kantarjian H, Shan J, Smith T, et al. Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia. Cancer. 2001;92:2501-2507.
24. Kantarjian H, Keating MJ, Estey EH, et al. Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with alpha interferon and low-dose cytosine arabinoside. J Clin Oncol. 1992;10:772-778.